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Abstract
Cervical spinal cord injury (SCI) damages axons and motor neurons responsible for ipsilateral
forelimb function and causes demyelination and oligodendrocyte death. Inhibition of the
phosphatase and tensin homologue, PTEN, promotes neural cell survival, neuroprotection and
regeneration in vivo and in vitro. PTEN inhibition can also promote oligodendrocyte-mediated
myelination of axons in vitro likely through Akt activation. We recently demonstrated that acute
treatment with phosphatase PTEN inhibitor, bisperoxovanadium (bpV)-pic reduced tissue damage,
neuron death, and promoted functional recovery after cervical hemi-contusion SCI. Evidence
suggests bpV can promote myelin stability; however, bpV effects on myelination and
oligodendrocytes in contusive SCI models are unclear. We hypothesized that bpV could increase
myelin around the injury site through sparing or remyelination, and that bpV treatment may
promote increased numbers of oligodendrocytes. Using histological and immunofluorescence
labeling, we found that bpV treatment promoted significant spared white matter (30%; p < 0.01)
and Luxol Fast Blue (LFB)+ myelin area rostral (Veh: 0.56 ± 0.01 vs. bpV: 0.64 ± 0.02; p < 0.05)
and at the epicenter (Veh: 0.4175 ± 0.03 vs. bpV: 0.5400 ± 0.03; p < 0.05). VLF oligodendrocytes
were also significantly greater with bpV therapy (109 ± 5.3 vs. Veh: 77 ± 2.7/mm2; p < 0.01). In
addition, bpV increased mean motor neuron soma area versus vehicle-treatment (1.0 ± 0.02 vs.
Veh: 0.77 ± 0.02) relative to Sham neuron size. This study provides key insight into additional cell
and tissue effects that could contribute to bpV-mediated functional recovery observed after
contusive cervical SCI.
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Introduction
Traumatic spinal cord injury (SCI) physically damages long myelinated axon tracts of the
spinal cord and instigates biochemical events that cause widespread cellular and tissue
disruption around the site of primary injury. Within 24 hours following contusive SCI, gray
matter tissue and cells at the injury epicenter are destroyed due to trauma and necrosis [1].
Demyelination commences, distal segments of disrupted axons undergo Wallerian
degeneration and such axonopathology promotes delayed apoptotic cell death of associated
oligodendrocytes [2,3]. Clearance of debris by phagocytic macrophages follows
fragmentation and degeneration of myelin and degenerated axons [4].
In the days thereafter, glial cells react, proliferate and migrate which increases the number of
reactive astrocytes and microglia around the lesion. Oligodendrocytes, the myelinating cells
of the central nervous system (CNS) and their precursors (OPCs) mobilize toward the lesion,
but behave differently than other glia and are susceptible to death near the epicenter and
distal to the lesion [5–7]. Thus, many myelinated axons and oligodendrocytes suffer damage
and degeneration, interfering with proper signal conduction and associated functional
ability. Though oligodendrocytes begin axonal remyelination in the weeks to months
following injury, such myelination is incomplete and the prognosis for significantly
improved function is poor [4]. Endogenous mechanisms for initiating and stabilizing axonal
myelination may be diluted by pathological cellular stimulation resulting in an overall net
loss of myelinating cells, axons, and reduction in any remyelination effort.
Phosphatidylinositol-3-kinase (PI3K)/Akt signal transduction is important for
oligodendrocyte differentiation, maintenance and stability of myelin, and cell survival [8–
12]. We recently demonstrated that acute treatment of the small molecule,
bisperoxovanadium (bpV[pic]), promoted reduced lesion and cavity formation, improved
neural survival, and positively affected Akt and mammalian target of rapamycin (mTOR)
activity through inhibition of the lipid phosphatase and tensin homologue (PTEN) as a
potential mechanism of its action [13].
PTEN is highly expressed in penumbral oligodendrocytes following SCI, and upregulation
of PI3K/Akt/mTOR signaling promotes oligodendrocyte lineage cell survival and
myelination activity [14–18]. In this study, we hypothesized that bpV promotes sparing of
oligodendrocytes around the lesion and protects myelination of associated axons following
cervical SCI. Since bpV enhanced forelimb functional recovery and oligodendrocyte
protection in the ventrolateral funiculus (VLF), an important region for rat locomotor ability,
we examined whether bpV have an effect on protection/proliferation of oligodendrocytes in
this region due to its anatomical and functional importance [19–21].
We also anticipated that bpV may have a protective effect on neuronal atrophy as compared
to the non-treated controls. Our previous studies showed considerable autophagosome
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aggregation in cervical motor neurons following injury, and this activity may promote
atrophy of surviving motor neurons in the injury penumbra. As this aggregation was
reversed by bpV treatment, bpV could directly reduce potential neuronal atrophy observed
after SCI [13]. In summary, this study aimed to investigate bpV’s effects on oligodendrocyte
survival, myelin sparing, and motoneuron atrophy after cervical contusive SCI.
Materials and Methods
Cervical hemi-contusive SCI
Adult female Sprague-Dawley rats (200–250 g, Harlan) (n = 19) were randomly assigned to
either sham surgery (n = 3), vehicle (saline)-treatment (n = 8), or bpV treatment (n = 8). The
animals were anaesthetized intraperitoneally (IP) with ketamine (87 mg/kg)/xylazine (12
mg/kg), and sham surgery or unilateral cervical SCI was performed as modified from Gensel
et al [22]. The NYU/MASCIS Impactor (2.5 mm tip diameter, 10 g weight, dropped from a
height of 12.5 mm) was used to produce a moderate unilateral injury of the exposed spinal
cord [22, 23]. The animals then received a subcutaneous injection of 5 mL 0.9% saline for
hydration and were placed in temperature-controlled housing overnight. All surgical and
animal handling procedures were performed as approved under the Guide for the Care and
Use of Laboratory Animals (National Research Council) and the Guidelines of the Indiana
University School of Medicine Institutional Animal Care and Use Committee.
Bisperoxovanadium treatment
Two sets of rats were randomly designated for treatment with bpV(pic) (n = 8) (Enzo Life
Sciences) or vehicle (n = 8) with dosing modified from previous publication [24]. After
cervical hemi-SCI, animals either received an immediate IP injection of 200 μg/kg bpV(pic)
in 0.9% saline or vehicle (0.9% saline). A third group served as a surgical control group
(sham) and was also injected with vehicle according the prescribed dosing schedule (n = 3).
Animals received a second dose of vehicle or bpV(pic) at 2 hours post-injury, and twice
daily for 7 days (400μg/kg/d).
Histological analysis
Six weeks post-injury, tissue was collected and processed as previously published [25]. In
brief, a 10 mm cervical spinal cord segment including the injury epicenter was extracted and
cryo-sectioned transversely at 20 μm thickness on Superfrost Plus slides (Fisher Scientific).
Tissue was stained using cresyl violet acetate stain with eosin counterstaining (CVE) for
tissue lesion/sparing assessment. Serial sections with an interval of 0.5 mm along the length
of the cord were used for assessing spared white matter. Three to four sections of tissue at
the epicenter, and 2 mm rostral and caudal from each groups were selected and stained with
Luxol Fast Blue (LFB) for calculation of spared myelinated tissue. Spared white matter and
myelination area were calculated using Image J (NIH).
Immunofluorescence labeling of oligodendrocytes & quantification
Immunofluorescence labeling was performed as described in previous publication [13, 25].
Briefly, immunofluorescence labeling of oligodendrocytes ~2 mm rostral and caudal to the
epicenter was performed using different sets of samples from the same animal tissue as used
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for cresyl violet and LFB staining. Cord segments were incubated with primary antibody
mouse anti-CC1 (APC-7, 1:50; Calbiochem, Inc.), a marker for oligodendrocytes. The
following day, the sections were incubated with rhodamine-conjugated goat anti-mouse
antibody (1:200; Jackson ImmunoResearch Lab). Sections were coverslip mounted with
Fluoromount G (Southern Fluoromount) combined with Hoechst 33342 (1:100) for nuclear
staining. Pre-immune serum was used to confirm the specificity of the antibody. Images
were obtained with epifluoresecence-equipped Olympus BX60 microscope.
Quantification of surviving oligodendrocytes was performed in sections surrounding the
injury site. The VLF was selected as the region of interest due to the influence of C5 hemi-
contusion on this area, and it contains axons related to propriospinal transduction of motor
signaling and limb coordination [20, 21, 26, 27]. Three sections per animal with an interval
of 500 μm within ~1.5–3.0 mm rostral to the injury epicenter were selected for analysis via
methods modified from a previous report [7]. The VLF was anatomically approximated in
tissue sections as described by Cote et al. [28]. A pie grid divided into 16 equal sections was
superimposed over the tissue image, and the section highlighted in red in Figure 2A (the 6th
section clockwise from the dorsal midline of the grid) was designated as the VLF region of
interest for the given tissue section. The interface between the white and gray matter, the
dorsal and ventral margins of the grid section, and the lateral margin of the cord in this
region were outlined using Neurolucida software to demarcate the VLF area of interest. In
designated areas of intact ventrolateral white matter rostral to the injury site, the VLF area
was measured and CC1+ oligodendrocytes were quantified within this region using
automation within Microbrightfield Neurolucida software. Only clearly identifiable CC1+
cell soma co-labeled with nuclear stain were included for quantification. The data were
represented as the number of oligodendrocytes per mm2.
Assessment of penumbral motor neuron atrophy
To address whether bpV has an effect on prevention of neuronal atrophy in surviving motor
neurons around the site of injury, rat spinal sections in the sham, vehicle- and bpV-treated
groups at 6 weeks post-SCI were examined. Motor neuron atrophy was measured by
identifying 3 sections 400 μm apart spanning from ~1.5 to 3.0 mm both rostral and caudal
from the injury epicenter per animal. Motor neurons were defined as previously published
[13]. In brief, large evenly stained neurons in the ventral horn with nucleus in plane were
selected for all groups, and each was traced and area measured using ImageJ software. Sham
rat motor neuron area was normalized to 100% (1.0) and mean Vehicle- and bpV-treated
group measurements were displayed as percent change of the sham value. Approximately 40
motor neurons were measured per animal to obtain mean values for each group.
Statistical analysis
To determine significance between two groups, a two-tailed unpaired Student’s t-test was
used. Statistical significance between multiple groups was determined using a one-way
ANOVA with Newman-Keuls post-hoc analysis. All statistical values were calculated using
GraphPad Prism 5.0 software (GraphPad, Inc.), with a p value < 0.05 considered statistically
significant.
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Results
At 6 weeks post-SCI, animals treated with bpV exhibited increased white matter (p < 0.05;
Fig. 1A & D) and LFB+ myelin around and at the injury epicenter (p < 0.05; Fig. 1B & F)
compared with vehicle-treated SCI rats (Fig. 1C & E). Representative photomicrographs
illustrate these effects in the ipsilateral cervical spinal cord. Since white matter and myelin
were spared following bpV(pic) treatment, we investigated the survival of oligodendrocytes,
which are important for myelination in the VLF. Oligodendrocyte soma co-labelled with
CC1 and Hoechst nuclear stain in the VLF were quantified (Fig. 2B-C'). As shown in Fig.
2D & E, and graphically in Fig. 2F, bpV significantly enhanced the number of CC1+
oligodendrocytes in the VLF rostral to the injury epicenter. Furthermore, the soma area of
ventral horn motor neurons were significantly larger (~25%) than saline-treated animals
(Fig. 3A-C) and exhibited similar size and morphological appearance to sham-operated rats
(Fig. 3C).
Discussion
Increased white matter and myelinated axons might result from general neuroprotective
effects of bpV therapy, or alternatively, through bpV-mediated reparative processes [13]. As
shown in this report, bpV facilitated increased chronic white matter and myelination sparing
or repair (Fig. 1). The observed improvement in these parameters implicated a sparing or
increase of adult myelinating oligodendrocytes, quantification of CC1+ oligodendrocytes
was performed ~ 1.5 to 3 mm rostral, the distance at which significant neuron and tissue
sparing was observed within the VLF, an axon tract which served as an indicator of the
spread of white matter damage, and is involved in forelimb motor control and locomotor
coordination via propriospinal interenlargement connections [21, 22, 27]. Following cervical
hemi-contusive SCI, the lesion occupies considerable portions of the lateral and
ventrolateral funiculi at the epicenter and tapers when distances increase rostral and caudal
to the epicenter. As lesion is reduced, the VLF is spared at distances near the epicenter
allowing the examination of VLF at approximately 2 mm rostral & caudal to the epicenter as
a region of interest to assess bpV treatment effect [13]. We observed a significant increase in
oligodendrocytes within the VLF at these regions following bpV treatment compared to
vehicle-treated animals (Fig. 2D-F). As such, enhanced oligodendrocyte support or
remyelination of axons may have influenced the integrity and functionality of white matter
witnessed following treatment. Alternatively, reduced spread of secondary damage and
inflammation induced by bpV may have spared injury to all these cord structures,
contributing to overall neuroprotection. It has been shown that bpV compounds can also
enhance proliferation of oligodendrocyte precursors [29]; therefore bpV may have enhanced
proliferation of oligodendrocyte precursors resulting in the increased quantity of CC1+
oligodendrocytes observed following treatment. A combination of these effects is possible,
and further studies are needed to clarify specific influence of bpV on spared or newly
formed oligodendrocytes following SCI.
Damaged or denervated neurons exhibit soma atrophy after axonal injury [30, 31]. We found
that bpV either directly or indirectly ameliorated injury-induced reduction in soma size (Fig.
3A-C). The significant increase in soma size could be due to indirect reduction in spread of
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secondary damage and lesion size which could result in larger, more normal appearing
neuron soma in tissue surrounding the injury site. However, loss of PTEN function has been
shown to increase the size of neurons and brain tissue due to upregulated activation of
translational processes mediated by the Akt/mTOR signaling axis, adding a potentially
signal-mediated mechanistic effect of bpV effect on neural cell body size [32, 33].
Administration of bpV may have stimulated protein synthesis and growth of neurons
through PTEN inhibition and subsequent upregulation of mTOR activity indicating a more
active role for bpV in modulating cell soma size. Interestingly, neuron hypertrophy mediated
by PTEN loss has been shown to be independent of downstream ribosomal protein S6
Kinase 1 (S6K1), suggesting other pathways may be involved in this process in addition to
PI3K/Akt/mTOR signaling [34]. Further biochemical and cellular analysis are required to
better understand the exact processes by which bpV may mediate this effect following
injury.
In conclusion, we now know that systemic acute bpV treatment affords extensive
neuroprotection including lesion reduction, white matter and myelin sparing, and reduction
of cell death. Our current and previous findings also suggest cellular protection by bpV may
proceed through downregulation of autophagy and apoptosis. Due to the complexity of
signal interactions and positive and negative feedback mechanisms, elucidating specific
cellular and molecular effects of chemical therapeutics is difficult. Despite these obstacles,
this study furthers our knowledge of bpV’s action as a therapeutic compound, and it is clear
that it likely exhibits differential cell-specific effects while still promoting an overall
neuroprotective result, reducing cell death mechanisms, and promoting functional recovery
following cervical hemicontusion SCI. Further studies will elucidate more specific details of
Akt/mTOR effects of bpV therapy on oligodendrocytes, and other cell types; however, this
report stands as additional foundational evidence for the efficacy and potential mechanisms
of the use of bpV compounds as an acute treatment following traumatic cervical SCI.
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Highlights
• Rats treated with PTEN inhibitor bisperoxovanadium for cervical spinal cord
injury.
• White matter, myelin, and ventrolateral funiculus oligodendrocytes were spared.
• Injury-induced neuronal soma atrophy was reversed by bisperoxovanadium.
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Figure 1. bpV promoted spared white matter and myelin in the ipsilateral cord following
cervical hemicontusion SCI
A) Compared to saline (Veh)-treated rats, bpV significantly improved white matter sparing
in the injured cervical spinal cord 6 weeks post-SCI (p < 0.05). B) Likewise, cervical hemi-
SCI induced myelin loss was significantly attenuated 2 mm rostral and at the epicentre of
injury by bpV over the Vehicle-treatment group (p < 0.05). No significant difference was
observed in LFB+ myelin area of the ipsilateral cord caudal to the epicenter. Representative
micrographs of ipsilateral white matter (C, D) and myelination (E, F) are provided. Scale
bar: C – F = 500 μm.
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Figure 2. Injury-mediated reduction of CC1+ oligodendrocytes in the VLF was reversed by bpV
treatment
A) Schematic diagram for designating the VLF for CC1+ oligodendrocyte quantification per
section. The area shaded in red was used the outline the VLF for further analysis. B – C’)
Oligodendrocyte soma exhibiting co-labeling with Hoechst 33342 and CC1 (white
arrowheads) in the VLF. D – F) bpV treatment resulted in a greater quantity of
oligodendrocytes in the ipsilateral VLF over Veh-treated rats following cervical hemi-
contusion SCI (p < 0.01). Scale bar: A – C = 50 μm; C’ = 25 μm; D & E= 50 μm.
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Figure 3. bpV treatment increased spared motor neuron soma size
A – C) bpV treatment diminished atrophy of motor neuron soma rostral and caudal to the
injury site (p < 0.001). C) The final average soma area for bpV-treated rats was similar to
the average for sham animals. Saline vehicle-treated rats exhibited an overall average
atrophy of ~20% ipsilateral neuron soma size at 6 weeks post-SCI. Scale bar: A – B’ = 50
μm.
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